Chardan Capital Comments on Krystal Biotech FY2026 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – Chardan Capital issued their FY2026 EPS estimates for shares of Krystal Biotech in a research report issued on Thursday, February 20th. Chardan Capital analyst Y. Livshits forecasts that the company will post earnings per share of $9.95 for the year. Chardan Capital currently has a “Buy” rating and a $218.00 target price on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share.

A number of other research analysts also recently commented on KRYS. HC Wainwright reissued a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research report on Wednesday, February 19th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. Finally, Citigroup raised their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Krystal Biotech currently has a consensus rating of “Buy” and a consensus price target of $210.00.

Krystal Biotech Stock Performance

NASDAQ KRYS opened at $186.89 on Monday. The company has a market capitalization of $5.38 billion, a price-to-earnings ratio of 62.51 and a beta of 0.84. The company’s 50-day simple moving average is $157.85 and its two-hundred day simple moving average is $175.26. Krystal Biotech has a one year low of $125.85 and a one year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. During the same quarter last year, the business posted $0.30 EPS. The firm’s revenue for the quarter was up 116.4% on a year-over-year basis.

Institutional Trading of Krystal Biotech

Several large investors have recently bought and sold shares of KRYS. Wilmington Savings Fund Society FSB purchased a new stake in Krystal Biotech during the 3rd quarter worth approximately $40,000. GF Fund Management CO. LTD. acquired a new stake in Krystal Biotech during the 4th quarter valued at approximately $95,000. Huntington National Bank lifted its stake in Krystal Biotech by 97.6% during the 3rd quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after acquiring an additional 283 shares during the period. Blue Trust Inc. lifted its stake in Krystal Biotech by 242.4% during the 3rd quarter. Blue Trust Inc. now owns 582 shares of the company’s stock valued at $107,000 after acquiring an additional 412 shares during the period. Finally, Covestor Ltd lifted its stake in Krystal Biotech by 972.7% during the 4th quarter. Covestor Ltd now owns 708 shares of the company’s stock valued at $111,000 after acquiring an additional 642 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 14.10% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).